Hepatitis C Medicines
A Contract Award Notice
by NHS NATIONAL SERVICES SCOTLAND
- Source
- Find a Tender
- Type
- Framework (Goods)
- Duration
- not specified
- Value
- £4M-£4M
- Sector
- HEALTH
- Published
- 07 Feb 2022
- Delivery
- not specified
- Deadline
- n/a
Concepts
Location
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014
1 buyer
- NHS National Services Scotland Edinburgh
3 suppliers
- Abbvie Maidenhead
- Gilead Sciences London
- Merck Sharp & Dohme Hoddesdon
Description
The framework agreement is awarded for the supply of medicines used to treat Hepatitis C to NHS Scotland.
Lot Division
1 | Treatment Cost per Medicine This Framework Agreement is for the supply of medicines used in the treatment of Hepatitis C to NHSScotland. |
2 | Treatment Spend Cap This Framework Agreement is for the supply of branded medicines under a capped spend model used in the treatment of Hepatitis C to NHSScotland. |
Award Detail
1 | Abbvie (Maidenhead)
|
2 | Gilead Sciences (London)
|
3 | Merck Sharp & Dohme (Hoddesdon)
|
4 | Abbvie (Maidenhead)
|
5 | Gilead Sciences (London)
|
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
Legal Justification
This VEAT notice is to advise the need for modification to meet the additional demands of the Scottish Health and Social Care sector during the current Covid-19 pandemic and to maintain necessary supply due to circumstances unforeseen by the Authority in line with Regulation 72(1)(c) of the Public Contracts (Scotland) Regulations 2015
Other Information
** PREVIEW NOTICE, please check Find a Tender for full details. ** The estimated value(s) referred to in Section II.I.7 and both Lots covers the twelve (12) month modification period of the framework agreement. (SC Ref:682305)
Reference
- ocds-h6vhtk-0313c0
- FTS 003365-2022